{"name":"NeuroPhage Pharmaceuticals","permalink":"neurophage-pharmaceuticals","crunchbase_url":"http://www.crunchbase.com/company/neurophage-pharmaceuticals","homepage_url":"http://www.neurophage.com/","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"info@neurophage.com","phone_number":"617-714-5468","description":"","created_at":"Wed Mar 02 04:10:54 UTC 2011","updated_at":"Mon Mar 12 03:23:23 UTC 2012","overview":"<p>NeuroPhage Pharmaceuticals, Inc., a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.</p>","image":{"available_sizes":[[[150,62],"assets/images/resized/0012/4531/124531v1-max-150x150.png"],[[203,84],"assets/images/resized/0012/4531/124531v1-max-250x250.png"],[[203,84],"assets/images/resized/0012/4531/124531v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"President and CEO","person":{"first_name":"Jonathan","last_name":"Solomon","permalink":"jonathan-solomon","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$21.4M","funding_rounds":[{"round_code":"b","source_url":"http://www.neurophage.com/news.html","source_description":"NeuroPhage Pharmaceuticals closes $12.4M Series B round","raised_amount":12400000,"raised_currency_code":"USD","funded_year":2011,"funded_month":3,"funded_day":1,"investments":[{"company":{"name":"Shire","permalink":"shire","image":{"available_sizes":[[[150,44],"assets/images/resized/0009/6378/96378v1-max-150x150.png"],[[150,44],"assets/images/resized/0009/6378/96378v1-max-250x250.png"],[[150,44],"assets/images/resized/0009/6378/96378v1-max-450x450.png"]],"attribution":null}},"financial_org":null,"person":null},{"company":null,"financial_org":{"name":"MÃ©rieux DÃ©veloppement","permalink":"mrieux-dveloppement","image":null},"person":null}]},{"round_code":"b","source_url":"http://www.finsmes.com/2012/03/neurophage-pharmaceuticals-raises-9-0m-series-b-1-funding.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29","source_description":"NeuroPhage Pharmaceuticals Raises $9.0M in Series B-1 Funding","raised_amount":9000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":3,"funded_day":8,"investments":[{"company":null,"financial_org":null,"person":{"first_name":"Michael","last_name":"Grundman","permalink":"michael-grundman","image":null}}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"222 Third Street","address2":"Suite 3120","zip_code":"02142 ","city":"Cambridge","state_code":"MA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[{"description":"closed a $12.4M Series B round","stoned_year":2011,"stoned_month":3,"stoned_day":2,"source_url":"http://www.masshightech.com/stories/2011/02/28/daily45-New-NeuroPhage-funding-to-back-move-to-Alzheimers-trial.html","source_text":null,"source_description":"New NeuroPhage funding to back move to Alzheimer's trial","stoneable_type":"Company","stoned_value":null,"stoned_value_type":null,"stoned_acquirer":null,"stoneable":{"name":"NeuroPhage Pharmaceuticals","permalink":"neurophage-pharmaceuticals"}}],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}